About Us

Joey received his PhD in Computer Science from the University of Colorado where he focused on the intersection of AI and cancer genomics. From this, Joey developed the founding IP for Arpeggio. After training at Merck and FORMA Therapeutics, Joey founded Arpeggio with Laura and Tim. He was awarded Forbes 30-under-30 in 2019.

Joey Azofeifa, PhD

CEO & Co-founder

Leah received her PhD in Biochemistry from the University of Colorado where she used microscopy and genomics to study the role of zinc in transcriptional regulation. Prior to grad school, Leah worked at MA General Hospital where she screened cancer cell lines to identify novel therapeutics. At Arpeggio, Leah focuses on scaling and automating drug screening efforts.

Leah Damon, PhD

Scientist

Ardeshir received his PhD from UNC Chapel Hill where he studied molecular dynamics of diseased proteins. He went on to do his postdoctoral fellowship at AstraZeneca and then worked as an investigator at Novartis. Ardeshir leads Arpeggio's computational chemistry efforts, bridging the gap between AI, biology, and medicinal chemistry.

Ardeshir Goliaei, PhD

Computational Chemist

Carter received his BA from the University of Southern Maine where he studied general biology. He went on to investigate novel synthetic lethality relationships in DNA damage and repair pathways with the D’Andrea Laboratory at the Dana Farber Cancer Institute. At Arpeggio, Carter focuses on drug screening and model development.

Carter Grochala

Research Associate

Cole received his BA in Cell and Molecular Biology from the University of Colorado. He then investigated anesthetic drug discovery at the Anschutz Medical Campus. At Arpeggio, Cole works at the interface of drug screening, automation, and assay development.

Cole Liechty

Research Associate

Eric is a drug discovery and development executive with over 20 years of experience leading preclinical and translational teams at Pfizer, Ignyta, Plexxikon, and Kinnate Biopharma. His mission is in developing the next generation of inhibitors to combat drug resistance in cancer. Eric leads Arpeggio's drug discovery efforts.

Eric Martin, PhD

CSO

Laura received her BA in Psychology at the University of Nebraska. She went on to found and operate multiple companies while advising startups on rapid growth potential as a business operations consultant. Laura founded Arpeggio alongside Joey and Tim where she leads operations, financial management, and legal teams.

Laura Norris

COO & Co-founder

Casey received his BS in Biochemistry & Biophysics from RPI and went on to work as an automation engineer at AmeriDrug Labs, Pfizer Oncology, and Hamilton Robotics. Casey manages Arpeggio's automated drug transcriptomic screening platform.

Casey Pham

Automation Engineer

Tim received his PhD in Molecular Biology from the University of Colorado where he focused on mechanisms or eukaryotic transcription. After doing his postdoctoral fellowship at Harvard Med, Tim founded Arpeggio alongside Joey and Laura. Tim leads Arpeggio's transcriptomic drug screening efforts.

Tim Read, PhD

CTO & Co-founder

Jenna received her PhD from the University of Colorado where she focused on the mechanisms of RNA Pol II mediated transcription and collaborated with Syros Pharmaceuticals on a novel CDK7 inhibitor. At Arpeggio, Jenna focuses on target discovery and validation for transcriptional addiction mechanisms in cancer.

Jenna Rimel, PhD

Scientist

Taylor received her MA in Rhetoric from San Diego State University where she studied the way scientists communicate their data. For almost 10 years Taylor ran an organic chemistry lab at The Scripps Research Institute in La Jolla, CA. At Arpeggio, Taylor provides administrative and operational support for all employees.

Taylor Schwer

Administrative Manager

Dave has over 20 years of experience running and managing molecular biology labs at Harvard Medical School, Martek Biosciences, and the University of Colorado. At Arpeggio, Dave connects lab operations to our drug discovery initiatives.

Dave Simpson

Lab Operations Manager

Amit is an entrepreneur turned investor. As a highly-regarded physician, Amit combines practical knowledge across the healthcare value-chain investing as a general partner at Builders VC. He brings entrepreneurial and operational experience as the founder and CMO of Intrinsic Imaging, and advises Arpeggio on funding opportunities and growth challenges.

Amit Mehta, MD, FRCP

Board Director
Builders VC

Joe was the President and CEO of KBI Biopharma from 2002 to 2016, growing the company from 10 employees to 1000+. Joe is currently the President and CEO of Bioventure Partners where he advises early-stage companies like Arpeggio.

Joe McMahon

Strategic Advisor
KBI Biopharma

John started his career at Bristol-Myers Squibb as a group leader of discovery chemistry. Currently, John advises early-stage companies on their medicinal chemistry design and interfaces with CROs to drive fast and accurate preclinical development.

John Dickson, PhD

Medicinal Chemistry Advisor
Bristol-Myers Squibb

Dave started his career at GSK where he was the VP of Biological Platform Technology and Science, and more recently was the VP of Research Operations at Precision Biosciences. Dave advises Arpeggio on systems biology and our automated drug screening platform.

Dave Morris, PhD

Platform Automation Advisor
GSK

Bill has led IP for companies like Advanced LiquidLogic, Illumina, and Grail. At Arpeggio, Bill is critical in helping define our patent strategy and portfolio around both our platform and novel chemical entities.

Bill Barrett

WSGR Counsel
Illumina, GRAIL

Who we are

Our Support: